Clinical Trial Update: Infinnium-Core™ Registry for the Treatment of Patients With De Novo Coronary Lesions [Phase 4]

View source ↗

Summary

Phase 4 registry for Infinnium-Core in de novo coronary lesions sponsored by Sahajanand Medical Technologies Limited has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Snippet

Sponsor: Sahajanand Medical Technologies Limited | Conditions: Coronary Artery Disease | Phase 4 | Status: TERMINATED